실험실 개발 검사(LDT) 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Laboratory Developed Tests Market size is expected to reach USD 19.40 Billion in 2034 from USD 10.68 Billion (2025) growing at a CAGR of 6.86% during 2026-2034.

The Global Laboratory Developed Tests (LDTs) Market is expanding as healthcare providers seek specialized diagnostic solutions tailored to specific patient needs. LDTs play a critical role in detecting rare diseases, genetic conditions, and complex infections. Their flexibility and customization make them highly valuable in advanced clinical laboratories, particularly in oncology and personalized medicine applications.

Rising demand for early and accurate disease diagnosis is a major growth driver. Increasing cases of cancer, infectious diseases, and chronic conditions have encouraged laboratories to develop in-house testing solutions. Technological advancements in molecular diagnostics, next-generation sequencing, and biomarker identification are also supporting market expansion. Additionally, growing awareness about precision medicine is boosting the adoption of LDTs in clinical decision-making.

In the future, the market is expected to evolve with stronger regulatory frameworks and quality standards to ensure reliability and safety. Integration of artificial intelligence in diagnostics and expansion of genomic testing will further enhance test accuracy and efficiency. As healthcare systems prioritize personalized treatment approaches, laboratory developed tests are likely to remain a vital component of modern diagnostic services.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Test Type

• Clinical biochemistry
• Immunology
• Haematology
• Microbiology
• Molecular diagnostics
• Flow cytometry
• Histology/Cytology
• Other test types

By Application

• Oncology
• Genetics
• Infectious diseases
• Autoimmune disorders
• Neurology
• Mental/Behavioral disorder
• Nutritional & metabolic diseases
• Other applications

By End-use

• Hospital laboratories
• Diagnostic centers
• Clinical research organizations
• Academic and research institutes
• Other end-users

COMPANIES PROFILED

• 23andMe Inc, Abbott, BioRad Laboratories Inc, Eurofins Scientific, F HoffmannLa Roche Ltd, Illumina Inc, NeoGenomics Laboratories, OPKO Health Inc, QIAGEN, Quest Diagnostics Incorporated
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL LABORATORY DEVELOPED TESTS MARKET: BY TEST TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Test Type
• 4.2. Clinical biochemistry Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Immunology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Haematology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Microbiology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Molecular diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Flow cytometry Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Histology/Cytology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.9. Other test types Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL LABORATORY DEVELOPED TESTS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Genetics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Infectious diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Autoimmune disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Neurology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Mental/Behavioral disorder Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Nutritional & metabolic diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.9. Other applications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL LABORATORY DEVELOPED TESTS MARKET: BY END-USE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-use
• 6.2. Hospital laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Diagnostic centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Clinical research organizations Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Academic and research institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Other end-users Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL LABORATORY DEVELOPED TESTS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Test Type
  • 7.2.2 By Application
  • 7.2.3 By End-use
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Test Type
  • 7.3.2 By Application
  • 7.3.3 By End-use
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Test Type
  • 7.4.2 By Application
  • 7.4.3 By End-use
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Test Type
  • 7.5.2 By Application
  • 7.5.3 By End-use
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Test Type
  • 7.6.2 By Application
  • 7.6.3 By End-use
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL LABORATORY DEVELOPED TESTS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 23andMe Inc
  • 9.2.2 Abbott
  • 9.2.3 Bio-Rad Laboratories Inc
  • 9.2.4 Eurofins Scientific
  • 9.2.5 F. Hoffmann-La Roche Ltd
  • 9.2.6 Illumina Inc
  • 9.2.7 NeoGenomics Laboratories
  • 9.2.8 OPKO Health Inc
  • 9.2.9 QIAGEN
  • 9.2.10 Quest Diagnostics Incorporated